Microbiome Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Probiotics, Prebiotics, Synbiotics (Combination of Prebiotics and Probiotics)), By Disease Indication (Digestive-related Disorders (Crohn's Disease, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Others)), Metabolic Disorders (Obesity, Diabetes, Others), Respiratory Infections, Cancer, Immune System, Oral Diseases, Skin Infections, and Others) and Region Forecast 2021-2032

Microbiome therapeutics market was valued at US$ 1.3 billion in 2025 and is expected to reach US$ 6.0 billion by 2032, growing at a significant CAGR of 25.0% from 2026-2032. A microbiome is the genetic material of all microbes such as bacteria, viruses, fungi, and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third of bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant in oral health. The market plays a significant role in human, gut health and disease conditions. The global microbiome therapeutics market is still nascent stage, very few products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in terms of microbiome therapeutics market growth, product launches, research, and development activities. 

Growth in clinical research and technological advancements are creating favorable opportunities across the microbiome therapeutics market. The microbiome therapeutics market size is expected to benefit from increasing investments in live biotherapeutic products, microbiome-derived therapies, microbial consortia, and next-generation approaches. Fecal microbiota transplantation has also demonstrated the therapeutic potential of microbiome modulation, while ongoing research is supporting the development of more standardized and precisely targeted microbiome drugs. In addition, advances in microbiome sequencing, bioinformatics, synthetic biology, and microbial engineering are improving therapeutic discovery and development. Increasing clinical validation, strategic collaborations, and commercialization efforts are expected to accelerate microbiome therapeutics market growth, strengthening the long-term outlook for the global microbiome therapeutics industry.

However, bigger players in the microbiome therapeutics market are focused on providing funding, collaborating, and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging research activities. The launch of microbiome therapeutics products in the market is expected to fuel the demand of the market over the forecast.  

Key Takeaways

• Increasing investment in microbiome research and clinical development is accelerating market growth.
• Clostridioides difficile infection remains a major application area.
• Oral microbiome therapies are gaining popularity due to convenience and scalability.
• Strategic collaborations, partnerships, and funding are strengthening the microbiome therapeutics pipeline.
• Research is expanding beyond gastrointestinal diseases into oncology, metabolic, autoimmune, and inflammatory disorders.
• Personalized microbiome-based therapies represent a significant future growth opportunity.

Key Developments

• In August 2026, Vedanta Biosciences secured US$60 million in funding to support the development of its microbiome-based therapeutics and strengthen its leadership team ahead of pivotal Phase 3 data. The company is developing defined bacterial consortia as oral microbiome-based medicines.
• In October 2025, Ferring Pharmaceuticals announced that it was exploring strategic options for Rebyota, its FDA-approved microbiota-based therapy indicated for preventing recurrence of Clostridioides difficile infection in adults following antibiotic treatment.
• In December 2025, MaaT Pharma presented final pivotal Phase 3 ARES results for MaaT013 (Xervyteg) in patients with gastrointestinal acute graft-versus-host disease (GI-aGvHD). The study reported a 54% one-year overall survival rate, supporting the continued development of the microbiome-based therapy.
• In March 2025, MaaT Pharma reported positive outcomes from the final independent Data and Safety Monitoring Board review of its pivotal Phase 3 ARES study of MaaT013. The study had met its primary endpoint, with a 62% gastrointestinal overall response rate at Day 28, exceeding the predefined expected response rate of 38%.
• In August 2024, Nestlé Health Science announced the acquisition of the global rights to VOWST from Seres Therapeutics. The transaction gave Nestlé full control over the development, commercialization, and manufacturing of VOWST, an FDA-approved orally administered microbiota-based therapy for preventing recurrence of C. difficile infection.